Why have CHO cells become the dominant host system for the production of recombinant therapeutic proteins?

Why have CHO cells become the dominant host system for the production of recombinant therapeutic proteins?

- Biosafety: low tumorigenicity, few human pathogenic viruses can be propagated, no infective retroviruses detected so far
- Ease of gene transfer + possibility of gene amplification
- Manufacturing: rapid growth, suspension growth (scale up)
- High product quality: post-translational modifications similar as in human

Name 4 pharmaceuticals made in CHO cells

Name 4 pharmaceuticals made in CHO cells

- tPA: tissue plasminogen activator
- Monoclonal antibodies (Humira, Avastin, Herceptin)
- EPO: Erythropoietin
- Lantus (insulin)

Name 3 pharmaceuticals made in E. coli

Name 3 pharmaceuticals made in E. coli

- Human growth hormone
- Recombinant human insulin
- Interferons

Name 4 pharmaceuticals made in yeast (Saccharomyces cerevisiae)

Name 4 pharmaceuticals made in yeast (Saccharomyces cerevisiae)

- Hepatitis B Vaccine (subunit vaccine)
- Insulin
- Platelet-derived growth factor
- Hirudin